Literature DB >> 15193251

Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography.

Mei Tian1, Hong Zhang, Tetsuya Higuchi, Noboru Oriuchi, Keigo Endo.   

Abstract

PURPOSE: To assess and compare the usefulness of (11)C-Choline-positron emission tomography (PET) with that of 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG)-PET for the differentiation between benign and malignant in various tumors.
MATERIALS AND METHODS: We examined 38 consecutive patients with various tumors, including seven patients with brain tumors, two with oral cavity tumor, two with esophageal cancer, six with lung cancer, 11 with bone tumor, nine with soft tissue tumors, and one with myeloma. (11)C-Choline-PET and FDG-PET were performed from five minutes and 40 minutes, respectively, after injection of 275-455 MBq tracer. Tracer uptakes were evaluated by the standardized uptake value (SUV) and were analyzed in according to the pathologic data.
RESULTS: (11)C-Choline uptake in malignancies (3.9 +/- 1.7, n=24) was significantly higher than that in benign lesions (1.7 +/- 1.2, n=14) (P < 0.0001). On the other hand, the FDG uptake in malignancies was 4.9 +/- 2.0 (n=24) and was also significantly larger than that in benign lesions 1.6 +/- 1.3 (n=14) (P < 0.0001). The (11)C-Choline uptake in all the lesions correlated with FDG uptake (r=0.658, P < 0.02, n=38). According to the receiver operating characteristic (ROC) analysis, the area under the ROC curve for (11)C-Choline-PET was 0.871, and with no significant difference compared to FDG-PET with the area of 0.929.
CONCLUSIONS: This study demonstrated that (11)C-Choline-PET is similar to FDG-PET in differentiation between malignant and benign lesion in various tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193251     DOI: 10.1016/j.mibio.2004.02.003

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  5 in total

Review 1.  State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Authors:  Jolinta Lin; Seth Kligerman; Rakhi Goel; Payam Sajedi; Mohan Suntharalingam; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2015-02

2.  Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.

Authors:  Nicolas Spaeth; Matthias T Wyss; Jens Pahnke; Gregoire Biollaz; Amelie Lutz; Kerstin Goepfert; Gerrit Westera; Valerie Treyer; Bruno Weber; Alfred Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-15       Impact factor: 9.236

3.  Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.

Authors:  Andre A Konski; Jonathan D Cheng; Melvyn Goldberg; Tianyu Li; Alan Maurer; Jian Q Yu; Oleh Haluszka; Walter Scott; Neal J Meropol; Steven J Cohen; Gary Freedman; Louis M Weiner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-29       Impact factor: 7.038

4.  Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules.

Authors:  Majid Khalaf; Hani Abdel-Nabi; John Baker; Yiping Shao; Dominick Lamonica; Jayakumari Gona
Journal:  J Hematol Oncol       Date:  2008-09-22       Impact factor: 17.388

Review 5.  Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.

Authors:  Amarnath Challapalli; Eric O Aboagye
Journal:  Front Oncol       Date:  2016-02-29       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.